Palmar Bullous Blistering Induced by Erlotinib

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Inflammatory Myofibroblastic Tumor of the Left Main Stem Bronchus

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery Åslaug Helland, MD, PhD, Hege Marian Skaug, MSc, Lilach Kleinberg,

Tubular Tumor Growth Along Entire Biopsy Track of Brain Metastasis

Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia Hiroaki Tachi, MD, Toshihiro Shiozawa, MD, Chio Sakai, MD, Mariko Kasuga,

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.

ALK FISH and IHC: You Cannot Have One without the Other

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients Camilla Maria T. Sagerup, MD, Milada.

Electronic Updates for JTO Readers

Hedgehog Signaling Pathway and Lung Cancer

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Frank Detterbeck, MD Journal of Thoracic Oncology

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

Isotretinoin Plus Clindamycin Seem Highly Effective Against Severe Erlotinib-Induced Skin Rash in Advanced Non-small Cell Lung Cancer Paolo Bidoli, MD,

Volume 2, Issue 3, Pages (May 2016)

LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non- small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing.

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Chemokines in the Biology of Lung Cancer

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

A first start for lung transplantation?

Jennifer L. Dallas, MD, Michael A. Jantz, MD, Judith L

Mitotic Inhibitors Journal of Thoracic Oncology

A Translational View of the Molecular Pathogenesis of Lung Cancer

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Nivolumab-Induced Granulomatous Inflammation of the Pleura

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Shih-Chieh Chang, Cheng-Yu Chang, Chiung-Yu Chen, Chong-Jen Yu

Associations between TS, TTF-1, FR-α, FPGS, and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin.

Leonor Carneiro-Leão, MD, Josefina Rodrigues Cernadas, MD

Pulmonary Metastasectomy in Breast Cancer

Phase I Study of Lenalidomide in Solid Tumors

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Genetic Changes in Squamous Cell Lung Cancer: A Review

Bronchioloalveolar Carcinoma Presenting as Chronic Progressive Pulmonary Infiltrates in a Woman with HIV: A Diagnosis Worth Making Todd M. Erickson,

Ethnic Differences in the Management of Lung Cancer in New Zealand

European Lung Cancer Conference (ELCC) 2016 Organisation

Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,

S-1 Treatment for Chemorefractory Thymic Carcinoma

Pleural Metastases of Malignant Melanoma

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

David Garfield, MD Journal of Thoracic Oncology

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma

A B3 Type-Thymoma in a 7-Year-Old Child with Myasthenia Gravis

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Palmar Bullous Blistering Induced by Erlotinib Arne Berg, MD, PhD, Odd Terje Brustugun, MD, PhD, Marius Lund-Iversen, MD, Åslaug Helland, MD, PhD Journal of Thoracic Oncology Volume 6, Issue 5, (May 2011) DOI: 10.1097/JTO.0b013e318211136b Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Acute onset of palmar bullous dermatitis 23 days after the start of erlotinib. Picture taken on day 25, 2 days after the first appearance. Photo courtesy: Per Marius Didriksen, Oslo University Hospital. Journal of Thoracic Oncology 2011 6, DOI: (10.1097/JTO.0b013e318211136b) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Histological biopsy showing intraepidermal bullae of varying size (squares), spongiosis (long red arrow), subepithelial edema (short red arrow), and a dermal leukocytic infiltrate composed of lymphocytes and plasma cells (long black arrow), and eosinophils (short black arrow), consistent with a bullous drug reaction. Photo courtesy: Marius Lund-Iversen, Oslo University Hospital. Journal of Thoracic Oncology 2011 6, DOI: (10.1097/JTO.0b013e318211136b) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions